BioPerfectus will start the next "golden decade" with a new attitude and adopt a more international logo in a broader commercial market. We aim to create a stronger image that would build on the previous one and accurately describe who we are today: one of the global IVD suppliers with a mission to embrace the world with health.
Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.
SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).
Jiangsu BioPerfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) applied for the clinical evaluation in XYZ Laboratory (XYZ Laboratory 2009 Ranch Rd. 620 N, STE 325, Austin, TX 78732, USA), a CAP accredited CLIA certified high complexity clinical molecular diagnostic laboratory to perform and report the Bioperfectus Monkeypox Virus (MPXV) Fast Real Time PCR Kit.